{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:56:32Z","timestamp":1787061392280,"version":"build-2736575974"},"reference-count":110,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.bone.2021.115887","type":"journal-article","created":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T01:51:19Z","timestamp":1613440279000},"page":"115887","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Bisphosphonates in inflammatory rheumatic diseases"],"prefix":"10.1016","volume":"146","author":[{"given":"Pilar","family":"Peris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Monegal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00faria","family":"Gua\u00f1abens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2021.115887_bb0005","doi-asserted-by":"crossref","first-page":"154264","DOI":"10.1016\/j.metabol.2020.154264","article-title":"Extra-skeletal effects of bisphosphonates","volume":"110","author":"Panagiotakou","year":"2020","journal-title":"Metabolism."},{"key":"10.1016\/j.bone.2021.115887_bb0010","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/BF02061949","article-title":"The effects of disodium ethane-1-hydroxy-1, 1-diphosphonate on adjuvant induced arthritis in rats","volume":"9","author":"Francis","year":"1972","journal-title":"Calcif. Tissue Res."},{"key":"10.1016\/j.bone.2021.115887_bb0015","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bone.2011.04.022","article-title":"Bisphosphonates: the first 40\u00a0years","volume":"49","author":"Russell","year":"2011","journal-title":"Bone."},{"key":"10.1016\/j.bone.2021.115887_bb0020","article-title":"Pharmacology of bisphosphonates in pain [published online ahead of print, 2019 Jul 25]","author":"Tzschentke","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bone.2021.115887_bb0025","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.beem.2008.07.001","article-title":"Bisphosphonates: how they work","volume":"22","author":"Papaoulos","year":"2008","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2021.115887_bb0030","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.2174\/138161210793563635","article-title":"Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages","volume":"16","author":"Roelofs","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.bone.2021.115887_bb0035","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1359\/jbmr.091009","article-title":"Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo","volume":"25","author":"Roelofs","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.115887_bb0040","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s002239900353","article-title":"An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates","volume":"61","author":"Thi\u00e9baud","year":"1997","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2021.115887_bb0045","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1002\/jbmr.5650100617","article-title":"Interleukin-6 and the acute phase response during treatment of patients with Paget\u2019s disease with the nitrogen-containing bisphosphonate dimethyl aminohydroxypropylidene bisphosphonate","volume":"10","author":"Schweitzer","year":"1995","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.115887_bb0050","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/BF02556671","article-title":"The acute-phase response after bisphosphonate administration","volume":"41","author":"Adami","year":"1987","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2021.115887_bb0055","doi-asserted-by":"crossref","first-page":"115512","DOI":"10.1016\/j.bone.2020.115512","article-title":"Zoledronate decreases CTLA-4 in vivo and in vitro independently of its action on bone resorption","volume":"138","author":"Giusti","year":"2020","journal-title":"Bone."},{"issue":"2","key":"10.1016\/j.bone.2021.115887_bb0060","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2141.2008.07435.x","article-title":"Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP\/DMAPP","volume":"144","author":"Roelofs","year":"2009","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bone.2021.115887_bb0065","doi-asserted-by":"crossref","first-page":"215763","DOI":"10.1155\/2014\/215763","article-title":"The soluble form of CTLA-4 from serum of patients with autoimmune diseases regulates T-cell responses","volume":"2014","author":"Simone","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.bone.2021.115887_bb0070","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1002\/art.1780381211","article-title":"Long-term amelioration of rat adjuvant arthritis following systemic elimination of macrophages by clodronate-containing liposomes","volume":"38","author":"Kinne","year":"1995","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bone.2021.115887_bb0075","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/rheumatology\/38.9.818","article-title":"Liposomal clodronate eliminates synovial macrophages, reduces inflammation and ameliorates joint destruction in antigen-induced arthritis","volume":"38","author":"Richards","year":"1999","journal-title":"Rheumatology."},{"issue":"8","key":"10.1016\/j.bone.2021.115887_bb0080","doi-asserted-by":"crossref","first-page":"PL95","DOI":"10.1016\/S0024-3205(97)01178-8","article-title":"Effects of tiludronate and ibandronate on the secretion of proinflammatory cytokines and nitric oxide from macrophages in vitro","volume":"62","author":"M\u00f6nkk\u00f6nen","year":"1998","journal-title":"Life Sci."},{"key":"10.1016\/j.bone.2021.115887_bb0085","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/art.10097","article-title":"Tumor necrosis factor \u03b1-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin","volume":"46","author":"Redlinch","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bone.2021.115887_bb0090","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1002\/art.20382","article-title":"Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis","volume":"50","author":"Sims","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bone.2021.115887_bb0095","doi-asserted-by":"crossref","first-page":"R185","DOI":"10.1186\/ar2877","article-title":"A combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis","volume":"11","author":"Le Goff","year":"2009","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.bone.2021.115887_bb0100","doi-asserted-by":"crossref","first-page":"106534","DOI":"10.1016\/j.intimp.2020.106534","article-title":"Alendronate alleviates the symptoms of experimental autoimmune encephalomyelitis","volume":"84","author":"Jung","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bone.2021.115887_bb0105","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1002\/art.21824","article-title":"Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis","volume":"54","author":"Jarrett","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bone.2021.115887_bb0110","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/ard.48.5.396","article-title":"Clinical, biochemical, and radiographic effects of aminohydroxypropylidene bisphosphonate treatment in rheumatoid arthritis","volume":"48","author":"Ralston","year":"1989","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bone.2021.115887_bb0115","first-page":"474","article-title":"Bone resorption and inflammatory inhibition efficacy of intermittent cyclical etidronate therapy in rheumatoid arthritis","volume":"30","author":"Hasegawa","year":"2003","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bone.2021.115887_bb0120","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/BOR.0b013e328133f57b","article-title":"Antiinflammatory treatment with bisphosphonates in ankylosing spondylitis","volume":"19","author":"Toussirot","year":"2007","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.bone.2021.115887_bb0125","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1111\/odi.12908","article-title":"Alteration of macrophage viability, differentiation, and function by bisphosphonates","volume":"24","author":"Patntirapong","year":"2018","journal-title":"Oral Dis."},{"key":"10.1016\/j.bone.2021.115887_bb0130","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2174\/1568014024606539","article-title":"Bisphosphonates-anti-inflammatory properties","volume":"1","author":"Maksymowych","year":"2002","journal-title":"Curr. Med. Chem. Antiinflam. Anti-Allergic Agents"},{"key":"10.1016\/j.bone.2021.115887_bb0135","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1002\/jbmr.5650101115","article-title":"Inhibition of antigen-presenting cell function by alendronate in vitro","volume":"10","author":"Sansoni","year":"1995","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.115887_bb0140","first-page":"430","article-title":"Bisphosphonates for arthritis\u2014a confusing rationale","volume":"30","author":"Maksymowych","year":"2003","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bone.2021.115887_bb0145","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.2337\/db10-1210","article-title":"CD14 modulates inflammation-driven insulin resistance","volume":"60","author":"Fern\u00e1ndez-Real","year":"2011","journal-title":"Diabetes."},{"key":"10.1016\/j.bone.2021.115887_bb0150","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.cell.2007.05.047","article-title":"Endocrine regulation of energy metabolism by the skeleton","volume":"130","author":"Lee","year":"2007","journal-title":"Cell."},{"key":"10.1016\/j.bone.2021.115887_bb0155","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.mce.2009.04.004","article-title":"A paradigm of integrative physiology, the crosstalk between bone and energy metabolisms","volume":"310","author":"Confavreux","year":"2009","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.bone.2021.115887_bb0160","first-page":"2793","article-title":"Decrease in carotid intima-media thickness after 1-year therapy with etidronate for osteopenia associated with type 2 diabetes","volume":"85","author":"Koshiyama","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4 Suppl","key":"10.1016\/j.bone.2021.115887_bb0165","first-page":"38","article-title":"Bisphosphonates and atherosclerosis","volume":"32","author":"Fiore","year":"2009","journal-title":"J. Endocrinol. Investig."},{"key":"10.1016\/j.bone.2021.115887_bb0170","first-page":"115352","article-title":"Bisphosphonates as a treatment modality in osteoarthritis [published online ahead of print, 2020 Apr 2]","author":"Eriksen","year":"2020","journal-title":"Bone."},{"key":"10.1016\/j.bone.2021.115887_bb0175","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.cell.2010.06.003","article-title":"Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism","volume":"142","author":"Ferron","year":"2010","journal-title":"Cell."},{"key":"10.1016\/j.bone.2021.115887_bb0180","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00223-011-9515-z","article-title":"Risk of newly diagnosed type 2 diabetes is reduced in users of alendronate","volume":"89","author":"Vestergaard","year":"2011","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2021.115887_bb0185","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/dom.12678","article-title":"Antiresorptive therapy and newly diagnosed diabetes in women: a historical cohort study","volume":"18","author":"Yang","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.bone.2021.115887_bb0190","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1002\/jbmr.1865","article-title":"Effects of antiresorptive therapies on glucose metabolism: results from the FIT, HORIZON-PFT, and FREEDOM trials","volume":"28","author":"Schwartz","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.115887_bb0195","article-title":"Bisphosphonates and risk of cardiovascular events: a meta-analysis","volume":"10","author":"Kim","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.bone.2021.115887_bb0200","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1161\/CIRCULATIONAHA.113.001534","article-title":"Atorvastatin, etidronate, or both in patients at high risk for atherosclerotic aortic plaques: a randomized, controlled trial","volume":"127","author":"Kawahara","year":"2013","journal-title":"Circulation."},{"issue":"Suppl. 2","key":"10.1016\/j.bone.2021.115887_bb0205","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1007\/PL00004164","article-title":"Bisphosphonates: pharmacology, mechanisms of action and clinical uses","volume":"9","author":"Russell","year":"1999","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2021.115887_bb0210","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3390\/antiox9060503","article-title":"Structure-dependent effects of bisphosphonates on inflammatory responses in cultured neonatal mouse calvaria","volume":"9","author":"Suzuki","year":"2020","journal-title":"Antioxidants (Basel)"},{"issue":"10","key":"10.1016\/j.bone.2021.115887_bb0215","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1172\/JCI6800","article-title":"Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin","volume":"104","author":"Plotkin","year":"1999","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.bone.2021.115887_bb0220","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.bone.2006.02.060","article-title":"Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts\/osteocytes with novel analogs","volume":"39","author":"Plotkin","year":"2006","journal-title":"Bone."},{"issue":"6","key":"10.1016\/j.bone.2021.115887_bb0225","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","article-title":"Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy","volume":"19","author":"Russell","year":"2008","journal-title":"Osteoporos. Int."},{"issue":"1","key":"10.1016\/j.bone.2021.115887_bb0230","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/jcb.21983","article-title":"Inhibition of osteoblast function in vitro by aminobisphosphonates","volume":"106","author":"Orriss","year":"2009","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.bone.2021.115887_bb0235","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S8756-3282(98)00033-7","article-title":"Biphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo","volume":"22","author":"Giuliani","year":"1998","journal-title":"Bone."},{"issue":"8","key":"10.1016\/j.bone.2021.115887_bb0240","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1080\/00325481.2017.1362312","article-title":"Osteoblast as a target of anti-osteoporotic treatment","volume":"129","author":"Corrado","year":"2017","journal-title":"Postgrad. Med."},{"key":"10.1016\/j.bone.2021.115887_bb0245","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","article-title":"Rheumatoid arthritis","volume":"376","author":"Scott","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2021.115887_bb0250","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1136\/ard.2003.016808","article-title":"Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project)","volume":"63","author":"Kastbom","year":"2004","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bone.2021.115887_bb0255","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1136\/ard.62.2.120","article-title":"Anticitrullinated protein\/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage","volume":"62","author":"Meyer","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bone.2021.115887_bb0260","doi-asserted-by":"crossref","first-page":"17372","DOI":"10.1073\/pnas.1114465108","article-title":"Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage","volume":"108","author":"Shi","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bone.2021.115887_bb0265","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1172\/JCI60975","article-title":"Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin","volume":"122","author":"Harre","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bone.2021.115887_bb0270","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nrrheum.2012.153","article-title":"Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment","volume":"8","author":"Schett","year":"2012","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.bone.2021.115887_bb0275","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/nri2094","article-title":"Cytokines in the pathogenesis of rheumatoid arthritis","volume":"7","author":"McInnes","year":"2007","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bone.2021.115887_bb0280","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/nm1538","article-title":"Dickkopf-1 is a master regulator of joint remodeling","volume":"13","author":"Diarra","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.bone.2021.115887_bb0285","first-page":"1443","article-title":"Correlation between systemic osteoporosis and local bone erosion with rheumatoid arthritis patients in Chinese population","volume":"58","author":"Gong","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.bone.2021.115887_bb0290","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1002\/art.24551","article-title":"The relationship between focal erosions and generalized osteoporosis in postmenopausal women with rheumatoid arthritis","volume":"60","author":"Solomon","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bone.2021.115887_bb0295","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1136\/annrheumdis-2012-202958","article-title":"Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies","volume":"73","author":"Kleyer","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bone.2021.115887_bb0300","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s13075-016-1116-9","article-title":"Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis","volume":"18","author":"Bugatti","year":"2016","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.bone.2021.115887_bb0305","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/oxfordjournals.rheumatology.a031496","article-title":"Radiographic imaging: the \u201cgold standard\u201d for assessment of disease progression in rheumatoid arthritis","volume":"39","author":"Van der Heijde","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.bone.2021.115887_bb0310","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.3899\/jrheum.181095","article-title":"OMERACT definitions for ultrasonographic pathologies and elementary lesions of rheumatic disorders 15\u00a0years on","volume":"46","author":"Bruyn","year":"2019","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bone.2021.115887_bb0315","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.reuma.2009.03.002","article-title":"Valoraci\u00f3n por imagen de la artritis reumatoide precoz","volume":"6","author":"Narvaez Garc\u0131a","year":"2010","journal-title":"Reumatol. Clin."},{"key":"10.1016\/j.bone.2021.115887_bb0320","doi-asserted-by":"crossref","first-page":"R110","DOI":"10.1186\/ar1995","article-title":"Are bone erosions detected by magnetic resonance imaging and ultrasonography true erosions? A comparison with computed tomography in rheumatoid arthritis metacarpophalangeal joints","volume":"8","author":"D\u00f8hn","year":"2006","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.bone.2021.115887_bb0325","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bone.2021.115887_bb0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.bone.2021.115887_bb0335","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.18688.1","article-title":"Emerging therapies in rheumatoid arthritis: focus on monoclonal antibodies","volume":"8","author":"Senolt","year":"2019","journal-title":"F1000Res."},{"key":"10.1016\/j.bone.2021.115887_bb0340","doi-asserted-by":"crossref","first-page":"R76","DOI":"10.1186\/ar1943","article-title":"Bone erosions in rheumatoid arthritis can be repaired through reduction in disease activity with conventional disease-modifying antirheumatic drugs","volume":"8","author":"Ideguchi","year":"2006","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.bone.2021.115887_bb0345","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1136\/ard.2009.108332","article-title":"Repair of joint erosions in rheumatoid arthritis: prevalence and patient characteristics in a large inception cohort","volume":"69","author":"Van der Linden","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bone.2021.115887_bb0350","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1136\/ard.2009.119156","article-title":"Repair of erosions occurs almost exclusively in damaged joints without swelling","volume":"69","author":"Lukas","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bone.2021.115887_bb0355","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1136\/ard.2008.097048","article-title":"Erosive progression is minimal, but erosion healing rare, in patients with rheumatoid arthritis treated with adalimumab. A 1-year investigator-initiated follow-up study using high-resolution computed tomography as the primary outcome measure","volume":"68","author":"M\u00f8ller D\u00f8hn","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bone.2021.115887_bb0360","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/art.27252","article-title":"Periarticular bone structure in rheumatoid arthritis patients and healthy individuals assessed by high-resolution computed tomography","volume":"62","author":"Stach","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bone.2021.115887_bb0365","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1136\/annrheumdis-2012-202779","article-title":"EULAR definition of erosive disease in light of the 2010 ACR\/EULAR rheumatoid arthritis classification criteria","volume":"72","author":"van der Heijde","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bone.2021.115887_bb0370","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/art.1780140605","article-title":"Method of scoring the progression of radiologic changes in rheumatoid arthritis","volume":"14","author":"Sharp","year":"1971","journal-title":"Arthritis Rheum."},{"issue":"8646","key":"10.1016\/j.bone.2021.115887_bb0375","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0140-6736(89)92442-2","article-title":"Effects of hydroxychloroquine and sulfasalazine on progression of joint damage in rheumatoid arthritis","volume":"1","author":"Van der Heijde","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2021.115887_bb0380","first-page":"1385","article-title":"OMERACT rheumatoid arthritis magnetic resonance imaging studies. Core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system","volume":"30","author":"\u00d8stergaard","year":"2003","journal-title":"J. Rheumatol."},{"issue":"3","key":"10.1016\/j.bone.2021.115887_bb0385","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/art.1780390307","article-title":"Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial","volume":"39","author":"Eggelmeijer","year":"1996","journal-title":"Arthritis Rheum."},{"issue":"11","key":"10.1016\/j.bone.2021.115887_bb0390","first-page":"2016","article-title":"Clinical and biochemical response to single infusion of pamidronate in patients with active rheumatoid arthritis: a double blind placebo controlled study","volume":"21","author":"Eggelmeijer","year":"1994","journal-title":"J. Rheumatol."},{"issue":"9","key":"10.1016\/j.bone.2021.115887_bb0395","first-page":"2080","article-title":"Effects of high dose IV pamidronate on disease activity and bone metabolism in patients with active RA: a randomized, double-blind, placebo-controlled trial","volume":"30","author":"Lodder","year":"2003","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bone.2021.115887_bb0400","first-page":"468","article-title":"Two year randomized controlled trial of etidronate in rheumatoid arthritis: changes in serum aminoterminal telopeptides correlate with radiographic progression of disease","volume":"30","author":"Valleala","year":"2003","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bone.2021.115887_bb0405","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1136\/annrheumdis-2012-203171","article-title":"Periarticular and generalized bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial","volume":"73","author":"Jensen","year":"2014","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.bone.2021.115887_bb0410","first-page":"2318","article-title":"Evaluation of bone turnover and osteoclastic cytokines in early rheumatoid arthritis treated with alendronate","volume":"26","author":"Cantatore","year":"1999","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bone.2021.115887_bb0415","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1136\/annrheumdis-2018-214827","volume":"78","author":"Takeuchi","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bone.2021.115887_bb0420","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/acr.23133","article-title":"Repair of bone erosion in rheumatoid arthritis by denosumab: a high-resolution peripheral quantitative computed tomography study","volume":"69","author":"Yue","year":"2017","journal-title":"Arthritis Care Res."},{"issue":"154","key":"10.1016\/j.bone.2021.115887_bb0425","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.medcli.2019.12.005","article-title":"Effect of antiresorptive and bone forming treatments in bone erosions in rheumatoid arthritis","volume":"8","author":"Azuaga-Pi\u00f1ango","year":"2020","journal-title":"Med. Clin. (Barc.)"},{"key":"10.1016\/j.bone.2021.115887_bb0430","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/2040622317702363","article-title":"Emerging potential for bisphosphonates in the treatment of axial spondyloarthritis","volume":"8","author":"Sambataro","year":"2017","journal-title":"Ther. Adv. Chronic Dis."},{"key":"10.1016\/j.bone.2021.115887_bb0435","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1136\/ard.60.4.316","article-title":"Claudepierre. Immunohistological study of entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis","volume":"60","author":"Laloux","year":"2001","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bone.2021.115887_bb0440","first-page":"883","article-title":"Assessment of the efficacy of pamidronate in ankylosing spondylitis: an open prospective trial","volume":"51","author":"Santra","year":"2010","journal-title":"Singap. Med. J."},{"key":"10.1016\/j.bone.2021.115887_bb0445","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1136\/annrheumdis-2013-204938","article-title":"An open-label study of zoledronic acid (Aclasta 5\u00a0mg iv) in the treatment of ankylosing spondylitis","volume":"73","author":"Clunie","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bone.2021.115887_bb0450","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/rheumatology\/ket321","article-title":"Bisphosphonates vs infliximab in ankylosing spondylitis treatment","volume":"53","author":"Viapiana","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.bone.2021.115887_bb0455","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3109\/03009742.2015.1038300","article-title":"Effect of golimumab and pamidronate on clinical efficacy and MRI inflammation in axial spondyloarthritis: a 48-week open randomized trial","volume":"44","author":"Mok","year":"2015","journal-title":"Scand. J. Rheumatol."},{"key":"10.1016\/j.bone.2021.115887_bb0460","first-page":"445","article-title":"Clinical efficacy of oral alendronate in ankylosing spondylitis: a randomised placebo-controlled trial","volume":"35","author":"Coates","year":"2017","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.bone.2021.115887_bb0465","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/art.10139","article-title":"A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60\u00a0mg versus 10\u00a0mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis","volume":"46","author":"Maksymowych","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bone.2021.115887_bb0470","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.semarthrit.2012.05.006","article-title":"The SAPHO syndrome","volume":"42","author":"Nguyen","year":"2012","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.bone.2021.115887_bb0475","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1517\/13543784.15.10.1229","article-title":"Pharmacological management of SAPHO syndrome","volume":"15","author":"Olivieri","year":"2006","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.bone.2021.115887_bb0480","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/rheumatology\/keh149","article-title":"SAPHO syndrome treated with pamidronate: an open-label study of 10 patients","volume":"43","author":"Amital","year":"2004","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.bone.2021.115887_bb0485","first-page":"112","article-title":"Sustained remission of SAPHO syndrome with pamidronate: a follow-up of fourteen cases and a review of the literature","volume":"27","author":"Colina","year":"2009","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.bone.2021.115887_bb0490","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/RHU.0b013e318177a64f","article-title":"Efficacy of alendronate in the treatment of the SAPHO syndrome","volume":"14","author":"Fioravanti","year":"2008","journal-title":"J. Clin. Rheumatol."},{"key":"10.1016\/j.bone.2021.115887_bb0495","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/RHU.0b013e3181e9be89","article-title":"Successful treatment of SAPHO syndrome with Ibandronate","volume":"16","author":"Soyfoo","year":"2010","journal-title":"J. Clin. Rheumatol."},{"key":"10.1016\/j.bone.2021.115887_bb0500","first-page":"663","article-title":"Efficacy of bisphosphonates in patients with synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: a prospective open study","volume":"37","author":"Li","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.bone.2021.115887_bb0505","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1002\/art.20464","article-title":"Successful treatment of SAPHO syndrome with zoledronic acid","volume":"50","author":"Kopterides","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bone.2021.115887_bb0510","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jmhi.2015.04.002","article-title":"Implication of bisphosphonate use in the treatment of SAPHO syndrome: case report and discussion of current literature","volume":"9","author":"Gorecki","year":"2015","journal-title":"J. Med. Hypotheses Ideas."},{"issue":"6","key":"10.1016\/j.bone.2021.115887_bb0515","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1097\/RHU.0000000000001025","article-title":"Imaging follow-up of SAPHO syndrome treated with zoledronic acid","volume":"26","author":"Rodriguez-Garc\u00eda","year":"2020","journal-title":"J. Clin. Rheumatol."},{"key":"10.1016\/j.bone.2021.115887_bb0520","doi-asserted-by":"crossref","DOI":"10.1097\/RLU.0000000000000983","article-title":"FDG PET\/CT in early and late stages of SAPHO syndrome: two case reports with MRI and bone scintigraphy correlation","volume":"41","author":"Dong","year":"2016","journal-title":"Clin. Nucl. Med."},{"key":"10.1016\/j.bone.2021.115887_bb0525","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.crad.2011.08.014","article-title":"SAPHO: what radiologists should know","volume":"67","author":"Depasquale","year":"2012","journal-title":"Clin. Radiol."},{"key":"10.1016\/j.bone.2021.115887_bb0530","first-page":"13","article-title":"F-18 FDG PET\/CT in 26 patients with SAPHO syndrome: a new vision of clinical and bone scintigraphy correlation","volume":"22","author":"Sun","year":"2018","journal-title":"J. Orthop. Surg. Res."},{"key":"10.1016\/j.bone.2021.115887_bb0535","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jbspin.2019.06.005","article-title":"Treatment of chronic recurrent multifocal osteomyelitis with bisphosphonates in children","volume":"86","author":"Su\u0142ko","year":"2019","journal-title":"Joint Bone Spine."},{"key":"10.1016\/j.bone.2021.115887_bb0540","first-page":"318","article-title":"Permanent discontinuation of glucocorticoids in polymyalgia rheumatica is uncommon but may be enhanced by amino bisphosphonates","volume":"46","author":"Giollo","year":"2019","journal-title":"Rheumatol."},{"key":"10.1016\/j.bone.2021.115887_bb0545","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/10717544.2017.1422295","article-title":"Bone-targeted methotrexate-alendronate conjugate inhibits osteoclastogenesis in vitro and prevents bone loss and inflammation of collagen-induced arthritis in vivo","volume":"25","author":"Xie","year":"2018","journal-title":"Drug Deliv."},{"key":"10.1016\/j.bone.2021.115887_bb0550","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1021\/acs.bioconjchem.7b00008","article-title":"Tocilizumab-alendronate conjugate for treatment of rheumatoid arthritis","volume":"28","author":"Lee","year":"2017","journal-title":"Bioconjug. Chem."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328221000491?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328221000491?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:54:56Z","timestamp":1757613296000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328221000491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":110,"alternative-id":["S8756328221000491"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2021.115887","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bisphosphonates in inflammatory rheumatic diseases","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2021.115887","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115887"}}